The latest price target for Molecular Partners (NASDAQ:MOLN) was reported by JP Morgan on December 5, 2023. The analyst firm set a price target for $4.50 expecting MOLN to fall to within 12 months (a possible -19.93% downside). 1 analyst firms have reported ratings in the last year.

The latest analyst rating for Molecular Partners (NASDAQ:MOLN) was provided by JP Morgan, and Molecular Partners maintained their neutral rating.

The last upgrade for Molecular Partners AG happened on May 25, 2022 when Credit Suisse raised their price target to N/A. Credit Suisse previously had an underperform for Molecular Partners AG.

The last downgrade for Molecular Partners AG happened on August 29, 2022 when SVB Leerink changed their price target from $30 to $8 for Molecular Partners AG.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Molecular Partners, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Molecular Partners was filed on December 5, 2023 so you should expect the next rating to be made available sometime around December 5, 2024.

While ratings are subjective and will change, the latest Molecular Partners (MOLN) rating was a maintained with a price target of $6.60 to $4.50. The current price Molecular Partners (MOLN) is trading at is $5.62, which is out of the analyst’s predicted range.